Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag for chemotherapy-induced thrombocytopenia in breast cancer
ChiCTR2200062811Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Proportion of subjects with effective response after herombopag treatment. Started Jul 2022; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2200062811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062811.